Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-cash Items (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Non-cash Items for 15 consecutive years, with $15.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-cash Items fell 11.67% to $15.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $15.8 million, a 11.67% decrease, with the full-year FY2023 number at $444.2 million, up 3406.73% from a year prior.
  • Non-cash Items was $15.8 million for Q3 2025 at Gyre Therapeutics, up from $15.6 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $444.2 million in Q4 2023 to a low of $1.2 million in Q1 2021.
  • A 5-year average of $33.0 million and a median of $7.5 million in 2023 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 85.21% in 2021, then skyrocketed 3406.73% in 2023.
  • Gyre Therapeutics' Non-cash Items stood at $1.5 million in 2021, then surged by 737.19% to $12.7 million in 2022, then surged by 3406.73% to $444.2 million in 2023, then crashed by 95.98% to $17.9 million in 2024, then fell by 11.67% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Non-cash Items are $15.8 million (Q3 2025), $15.6 million (Q2 2025), and $16.2 million (Q1 2025).